试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-22
Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma
编号:NCT03617484登记状态:入组前撤回企业 / 申办者:University of Michigan Rogel Cancer Center
药物 / 成分:Bortezomib、Ibrutinib
登记的停止原因(原文):Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a suspension of IRB approval.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-22
A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil
编号:NCT04283136登记状态:入组前撤回企业 / 申办者:UCB Biopharma SRL
药物 / 成分:Padsevonil type 1 Tablet 200 mg、Padsevonil type 2 Tablet、Padsevonil type 3 Tablet、Padsevonil type 4 Tablet
登记的停止原因(原文):Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-18
Preoperative Corticosteroid Epidural Injection and Lumbar Decompression Surgery Outcomes
编号:NCT03543033登记状态:入组前撤回企业 / 申办者:Lahey Clinic
药物 / 成分:Corticosteroid injection
登记的停止原因(原文):The study was closed by the investigators due to lack of study population to enroll.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-18
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
编号:NCT04361552登记状态:入组前撤回企业 / 申办者:Emory University
药物 / 成分:Best Practice、Tocilizumab
登记的停止原因(原文):Study abandoned due to drug billing issues
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-17
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
编号:NCT03987750登记状态:入组前撤回企业 / 申办者:Zambon SpA
药物 / 成分:Safinamide Methanesulfonate 150mg、Safinamide Methanesulfonate 100mg、Safinamide Methanesulfonate matching placebo
登记的停止原因(原文):drug development plan has been updated
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-16
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19
编号:NCT04285190登记状态:入组前撤回企业 / 申办者:Tasly Pharmaceuticals, Inc.
药物 / 成分:T89
登记的停止原因(原文):The COVID-19 pandemic in China has ended completely. As a result, patient recruiting is impossible in China.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-12
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
编号:NCT00753740登记状态:入组前撤回企业 / 申办者:NewLink Genetics Corporation
药物 / 成分:IT-101 (12mg/m2/dose)、IT-101 (15mg/m2/dose)、5% Dextrose (Placebo)
登记的停止原因(原文):Poor trial recruitment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-12
Mechanisms of Refractory Hypertension (Carvedilol)
编号:NCT02357004登记状态:入组前撤回企业 / 申办者:University of Alabama at Birmingham
药物 / 成分:Carvedilol、Chlorthalidone
登记的停止原因(原文):Change in priority of interventional protocols
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-12
Postoperative Pain and Headache After Craniotomy
编号:NCT03908944登记状态:入组前撤回企业 / 申办者:Steven Edelstein
药物 / 成分:Methadone、Standard of Care
登记的停止原因(原文):PI- Dr. Jellish passed away. The study was terminated with the IRB
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-06-12
Effects of Food on the Pharmacokinetics of DWJ1458 in Healthy Adults
编号:NCT04393597登记状态:入组前撤回企业 / 申办者:Daewoong Pharmaceutical Co. LTD.
药物 / 成分:DWJ1458 (fasted)、DWJ1458 (fed)
登记的停止原因(原文):We decided to discontinue this particular clinical study through internal discussion.
查看官方原始记录 ↗